National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 10) (PB 100 of 2018) (Cth)
PB 100 of 2018
National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 10)
National Health Act 1953
___________________________________________________________________________
I, SEAN LANE, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 28 November 2018
SEAN LANE
Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
___________________________________________________________________________
Name of Instrument
(1)This Instrument is the National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 10).
(2)This Instrument may also be cited as PB 100 of 2018.
Commencement
This Instrument commences on 1 December 2018.
Amendment of National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015)
Schedule 1 amends the National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015).
Schedule 1 Amendments
Schedule 1, after entry for Dipyridamole with aspirin in the form Capsule 200 mg (sustained release)-25 mg
insert:
| Dolutegravir with rilpivirine | Tablet containing dolutegravir 50 mg (as sodium) with rilpivirine 25 mg (as hydrochloride) | 20 | 60 | 5 |
Schedule 1, after entry for Erlotinib in the form Tablet 25 mg (as hydrochloride)
insert:
| Ertugliflozin | Tablet 5 mg | 20 | 28 | 5 |
| Ertugliflozin | Tablet 15 mg | 20 | 28 | 5 |
| Ertugliflozin with metformin | Tablet containing 2.5 mg ertugliflozin with 500 mg metformin hydrochloride | 20 | 56 | 5 |
| Ertugliflozin with metformin | Tablet containing 2.5 mg ertugliflozin with 1 g metformin hydrochloride | 20 | 56 | 5 |
| Ertugliflozin with metformin | Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride | 20 | 56 | 5 |
| Ertugliflozin with metformin | Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride | 20 | 56 | 5 |
| Ertugliflozin with sitagliptin | Tablet containing 5 mg ertugliflozin with 100 mg sitagliptin | 20 | 28 | 5 |
| Ertugliflozin with sitagliptin | Tablet containing 15 mg ertugliflozin with 100 mg sitagliptin | 20 | 28 | 5 |
Schedule 1, after entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet
insert:
| Mesalazine | Tablet 1 g (enteric coated) | 20 | 120 | 5 |
Schedule 1, after entry for Methotrexate in the form Injection 7.5 mg in 0.15 mL pre‑filled syringe
insert:
| Methotrexate | Injection 7.5 mg in 0.3 mL pre-filled syringe | 20 | 4 | 5 |
Schedule 1, after entry for Methotrexate in the form Injection 10 mg in 0.2 mL pre‑filled syringe
insert:
| Methotrexate | Injection 10 mg in 0.4 mL pre-filled syringe | 20 | 4 | 5 |
Schedule 1, after entry for Methotrexate in the form Injection 15 mg in 0.3 mL pre‑filled syringe
insert:
| Methotrexate | Injection 15 mg in 0.6 mL pre-filled syringe | 20 | 4 | 5 |
Schedule 1, after entry for Methotrexate in the form Injection 20 mg in 0.4 mL pre‑filled syringe
insert:
| Methotrexate | Injection 20 mg in 0.8 mL pre‑filled syringe | 20 | 4 | 5 |
Schedule 1, after entry for Methotrexate in the form Injection 25 mg in 0.5 mL pre‑filled syringe
insert:
| Methotrexate | Injection 25 mg in 1 mL pre-filled syringe | 20 | 4 | 5 |
Schedule 1, after entry for Olaparib in the form Capsule 50 mg
insert:
| Olaparib | Tablet 100 mg | 20 | 112 | 5 |
| Olaparib | Tablet 150 mg | 20 | 112 | 5 |
0
0
0